These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18327151)

  • 1. Correspondence.
    Uparkar M; Maiti A; Natarajan S
    Retina; 2008 Mar; 28(3):527; author reply 527-8. PubMed ID: 18327151
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing ranibizumab with bevacizumab.
    Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
    Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
    [No Abstract]   [Full Text] [Related]  

  • 3. Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration.
    Falkenstein IA; Cheng L; Morrison VL; Kozak I; Tammewar AM; Freeman WR
    Retina; 2007; 27(6):701-6. PubMed ID: 17621178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab.
    Lucas RS; McKee HD; Lee LR
    Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
    [No Abstract]   [Full Text] [Related]  

  • 5. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system.
    Spaide RF
    Am J Ophthalmol; 2009 Jul; 148(1):1-3. PubMed ID: 19540983
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
    Spandau UH; Jonas JB
    Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
    Jonas JB; Tao Y; Rensch F
    Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
    Bom Aggio F; Eid Farah M; Melo GB
    Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
    [No Abstract]   [Full Text] [Related]  

  • 9. Necessity of paracentesis before or after intravitreal injection of bevacizumab.
    Huang WC; Lin JM; Chiang CC; Tsai YY
    Arch Ophthalmol; 2008 Sep; 126(9):1314-5; author reply 1315. PubMed ID: 18779502
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-VEGF therapy: riding the wave of change.
    Hunyor AP
    Clin Exp Ophthalmol; 2008 Jul; 36(5):401-2. PubMed ID: 18925912
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
    Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
    Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.
    Farah SE
    Ophthalmic Surg Lasers Imaging; 2008; 39(4):294-8. PubMed ID: 18717434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
    Retina; 2006; 26(9):994-8. PubMed ID: 17151485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapy in neovascular age-related macular degeneration.
    Lin RC; Rosenfeld PJ
    Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
    [No Abstract]   [Full Text] [Related]  

  • 16. Controversies in the treatment of wet age-related macular degeneration.
    Moreno SF; Paloma JB
    Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
    Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
    Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.
    Aggio FB; Melo GB; Höfling-Lima AL; Eid Farah M
    Acta Ophthalmol Scand; 2006 Dec; 84(6):831-3. PubMed ID: 17083553
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravitreal avastin: the low cost alternative to lucentis?
    Rosenfeld PJ
    Am J Ophthalmol; 2006 Jul; 142(1):141-3. PubMed ID: 16815262
    [No Abstract]   [Full Text] [Related]  

  • 20. [Introduction to the topic: anti-VEGF therapy in the management of AMD].
    Meyer CH
    Ophthalmologe; 2008 Feb; 105(2):123-4. PubMed ID: 18256843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.